FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313707008> ?p ?o ?g. }

• W4313707008 endingPage "3034" @default.
• W4313707008 startingPage "3025" @default.
• W4313707008 abstract "Abstract Objectives Identifying that dysfunction of the IL-23/17 axis underlies PsA has led to the development of effective targeted therapies such as the IL-17A inhibitor secukinumab. As IL-17A stimulates the secretion of neutrophil chemoattractants, such as CXCL8 (IL-8), we examined the effect of secukinumab on neutrophil function in PsA. Methods Nineteen patients with active PsA were treated with secukinumab. Clinical response [PsA Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI)] and peripheral blood neutrophil function (apoptosis, receptor expression, phagocytosis/killing, chemotaxis and RNA expression) were measured at 12 week intervals for 48 weeks and compared with age- and sex-matched healthy controls. Results At 12 weeks, 12/16 (75%) patients had a PsARC response (100% at 36 weeks) and 10/14 (71%) achieved a 90% PASI response. At baseline, there were no differences in PsA neutrophil reactive oxygen species generation, constitutive or cytokine-delayed apoptosis, chemotaxis or phagocytosis of opsonized Staphylococcus aureus compared with healthy controls. Similarly, there were no differences in these functions from baseline to 12 weeks of therapy. However, surface levels of CD11b/CD18 and CD63 increased and expression of CD16 decreased during therapy. In addition, in a subgroup of early (12 week) responders to secukinumab, RNA sequencing revealed transcriptome changes predicting down-regulation of cytokine signalling and chemotaxis pathways and up-regulation of de novo gene expression pathways, including translation initiation, mRNA catabolism and translation. Conclusion Complex changes in the properties of circulating neutrophils occur with secukinumab treatment in PsA that may indicate altered responsiveness to changes in both local and systemic levels of pro-inflammatory cytokines. However, host defence processes of neutrophils were unaltered." @default.
• W4313707008 created "2023-01-08" @default.
• W4313707008 creator A5011580400 @default.
• W4313707008 creator A5029137825 @default.
• W4313707008 creator A5039154503 @default.
• W4313707008 creator A5071732240 @default.
• W4313707008 creator A5075906091 @default.
• W4313707008 creator A5076753087 @default.
• W4313707008 creator A5078491446 @default.
• W4313707008 creator A5082904031 @default.
• W4313707008 date "2023-01-06" @default.
• W4313707008 modified "2023-09-23" @default.
• W4313707008 title "Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence" @default.
• W4313707008 cites W1964296409 @default.
• W4313707008 cites W1982598880 @default.
• W4313707008 cites W1996688998 @default.
• W4313707008 cites W1999048147 @default.
• W4313707008 cites W2006513975 @default.
• W4313707008 cites W2020541351 @default.
• W4313707008 cites W2029617490 @default.
• W4313707008 cites W2032653457 @default.
• W4313707008 cites W2041084308 @default.
• W4313707008 cites W2074045776 @default.
• W4313707008 cites W2093785176 @default.
• W4313707008 cites W2100305481 @default.
• W4313707008 cites W2103524303 @default.
• W4313707008 cites W2112530582 @default.
• W4313707008 cites W2114104545 @default.
• W4313707008 cites W2115704131 @default.
• W4313707008 cites W2118706017 @default.
• W4313707008 cites W2138207763 @default.
• W4313707008 cites W2153962607 @default.
• W4313707008 cites W2162143298 @default.
• W4313707008 cites W2162577685 @default.
• W4313707008 cites W2169353806 @default.
• W4313707008 cites W2171437346 @default.
• W4313707008 cites W2171581427 @default.
• W4313707008 cites W2320328374 @default.
• W4313707008 cites W2336473632 @default.
• W4313707008 cites W2514588652 @default.
• W4313707008 cites W2530462654 @default.
• W4313707008 cites W2558678787 @default.
• W4313707008 cites W2572897530 @default.
• W4313707008 cites W2620710772 @default.
• W4313707008 cites W2622994728 @default.
• W4313707008 cites W27810290 @default.
• W4313707008 cites W2794504806 @default.
• W4313707008 cites W2797662273 @default.
• W4313707008 cites W2799802646 @default.
• W4313707008 cites W2805879602 @default.
• W4313707008 cites W2805937472 @default.
• W4313707008 cites W2884690151 @default.
• W4313707008 cites W2886007274 @default.
• W4313707008 cites W2947452967 @default.
• W4313707008 cites W2950464315 @default.
• W4313707008 cites W2953889774 @default.
• W4313707008 cites W2959026202 @default.
• W4313707008 cites W2964369209 @default.
• W4313707008 cites W2977560074 @default.
• W4313707008 cites W2980604773 @default.
• W4313707008 cites W2983840415 @default.
• W4313707008 cites W3031871627 @default.
• W4313707008 doi "https://doi.org/10.1093/rheumatology/kead007" @default.
• W4313707008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36617171" @default.
• W4313707008 hasPublicationYear "2023" @default.
• W4313707008 type Work @default.
• W4313707008 citedByCount "0" @default.
• W4313707008 crossrefType "journal-article" @default.
• W4313707008 hasAuthorship W4313707008A5011580400 @default.
• W4313707008 hasAuthorship W4313707008A5029137825 @default.
• W4313707008 hasAuthorship W4313707008A5039154503 @default.
• W4313707008 hasAuthorship W4313707008A5071732240 @default.
• W4313707008 hasAuthorship W4313707008A5075906091 @default.
• W4313707008 hasAuthorship W4313707008A5076753087 @default.
• W4313707008 hasAuthorship W4313707008A5078491446 @default.
• W4313707008 hasAuthorship W4313707008A5082904031 @default.
• W4313707008 hasConcept C126322002 @default.
• W4313707008 hasConcept C13373296 @default.
• W4313707008 hasConcept C160448771 @default.
• W4313707008 hasConcept C170493617 @default.
• W4313707008 hasConcept C203014093 @default.
• W4313707008 hasConcept C2776260265 @default.
• W4313707008 hasConcept C2777077863 @default.
• W4313707008 hasConcept C2778690821 @default.
• W4313707008 hasConcept C2779786854 @default.
• W4313707008 hasConcept C54166955 @default.
• W4313707008 hasConcept C71924100 @default.
• W4313707008 hasConcept C8891405 @default.
• W4313707008 hasConceptScore W4313707008C126322002 @default.
• W4313707008 hasConceptScore W4313707008C13373296 @default.
• W4313707008 hasConceptScore W4313707008C160448771 @default.
• W4313707008 hasConceptScore W4313707008C170493617 @default.
• W4313707008 hasConceptScore W4313707008C203014093 @default.
• W4313707008 hasConceptScore W4313707008C2776260265 @default.
• W4313707008 hasConceptScore W4313707008C2777077863 @default.
• W4313707008 hasConceptScore W4313707008C2778690821 @default.
• W4313707008 hasConceptScore W4313707008C2779786854 @default.
• W4313707008 hasConceptScore W4313707008C54166955 @default.

• next